Product Description
Idarubicin is used treat acute myelogenous leukemia (AML; a type of cancer of the white blood cells) in combination with other medications. Idarubicin is in a class of medications called anthracyclines. It works by slowing or stopping the growth of cancer cells in your body.15-Dec-2012Ready-to-Use Sterile FormulationIdarubicin injection is conveniently available in a ready-to-administer form, eliminating the need for reconstitution. This streamlines pharmacy workflows, enhances patient safety, and reduces preparation errors. The product is supplied in a sterile, clear red-orange solution contained within glass vials, specially sealed to maintain integrity.
Strict Compliance and Safe HandlingManufactured to meet international standards-including WHO, US FDA, or EMA guidelines when applicable-the injection must be handled with full cytotoxic precautions. All personnel should use gloves and protective gear during preparation and administration, and all waste should be disposed of according to hazardous pharmaceutical protocols.
Optimal Storage and Shelf LifeFor maximum efficacy and safety, idarubicin injection should be stored below 25C, protected from light, and never frozen. Each vial remains stable for up to 24 months unopened. Secondary box packaging ensures safe transportation and storage until use in clinical settings.
FAQ's of idarubicin injection:
Q: How should idarubicin injection be administered to patients?
A: Idarubicin injection is administered intravenously, either as an infusion or a bolus, under the supervision of qualified healthcare professionals. Dosage and infusion rates are determined according to clinical protocol and patient requirements.
Q: What are the compatible diluents for idarubicin injection?
A: For infusion, idarubicin injection is compatible with 0.9% saline or 5% dextrose solutions. The injection is provided ready-to-use, so further reconstitution is unnecessary for these presentations.
Q: When is idarubicin injection indicated?
A: Idarubicin is most commonly indicated for treating patients with acute myeloid leukemia (AML), especially those who have relapsed or are refractory to first-line treatments. It may also be used in other hematologic malignancies as directed by clinical protocols.
Q: Where should idarubicin injection be stored before use?
A: The vials should be stored below 25C (77F), protected from light, and must not be frozen. Proper storage ensures stability of the medication throughout its shelf life of 24 months (unopened).
Q: What safety precautions must be observed when handling idarubicin injection?
A: Idarubicin is classified as a cytotoxic agent, requiring personnel to wear gloves and appropriate protective equipment during preparation and administration. All waste, including vials and consumables, should be disposed of as hazardous pharmaceutical waste according to local guidelines.
Q: What are the benefits of using ready-to-use idarubicin injection vials?
A: The ready-to-use formulation eliminates the need for on-site reconstitution, minimizing the risk of dosing errors, contamination, and exposure to cytotoxic drugs, thereby streamlining administration and improving safety for both patients and healthcare staff.